GET DAILY SIGNALS4D Molecular Therapeutics (FDMT): Is +148% Upside to the $31 Analyst Target Realistic?
Key Takeaways
- The central $31 price target is the arithmetic mean of seven recent, individually attributable analyst price targets, rounded from roughly $30.57.
- With shares near $12.48, reaching $31 would require a rise of about 148% — a very large move even by volatile biotech standards.
- Current verified targets span approximately $20 to $37, reflecting sharply divided views on clinical and commercial execution risk.
- The strongest support comes from the Phase 3 program for 4D-150 in wet age-related macular degeneration (AMD), plus a cash runway extending into 2028.
- The biggest risks are binary clinical-trial outcomes, ongoing losses with limited revenue, elevated short interest, and recent insider selling.
- Explore the company's Major News and Today's Price Move, review the Forecast, and check Earnings on dedicated pages for deeper coverage.
- To surface opportunities and shifting trends across the market, explore Trending AI Robots.
Analyst Price Targets and Consensus View
4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage genetic-medicines company. Reviewing seven recent, named price targets — B. Riley Securities at $37, H.C. Wainwright at $36, RBC Capital at $35, Bank of America Securities at $33, Barclays at $28, Chardan Capital at $25, and Cantor Fitzgerald at $20 — yields an arithmetic mean of about $30.57, rounded here to $31. The range is unusually wide, roughly $20 to $37, a sign of genuine disagreement rather than a tight consensus. Broader aggregators report similar figures: StockAnalysis lists an average near $28 with 12 analysts, while MarketBeat shows about $30 across 11, so the $31 target sits comfortably within published consensus estimates. Ratings skew bullish, with most firms at Buy, Outperform, or Overweight. Morgan Stanley maintains a Hold without a price target, and Cantor Fitzgerald upgraded the stock to Overweight in September 2026. Bullish analysts emphasize 4D-150's differentiated, potentially durable treatment profile; more cautious targets reflect clinical, regulatory, and financing uncertainty. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares closed near $12.48 in early November 2026, giving the company a market capitalization of roughly $690 million. Reaching $31 implies upside of about 148%, a very large move that would exceed the stock's 52-week high of $16.93 by a wide margin. That path almost certainly depends on positive Phase 3 data for 4D-150 in wet AMD, where the 4FRONT program has completed enrollment early in its second pivotal trial, with key readouts expected in 2027. Between now and then, the shares are likely to trade more on data milestones and financing headlines than on quarterly financials, given that the company is not yet profitable.
What Could Support a Move Toward the Target
The core thesis is 4D-150, an intravitreal gene therapy designed to reduce the injection burden of standard anti-VEGF treatments in wet AMD and diabetic macular edema. Encouraging Phase 2 durability data and efficient Phase 3 enrollment support the bull case. The balance sheet is also a strength: roughly $361 million in cash and a net cash position near $391 million (about $7 per share), supplemented by a credit facility, is expected to fund operations into the second half of 2028. A favorable data readout, further positive analyst revisions, or a partnership could all compress the wide valuation gap between the current price and the target.
What Could Prevent the Target From Being Reached
The risks are substantial. The company posts meaningful losses — consensus forecasts roughly a $4.15 per-share loss for 2026 — with revenue that is milestone-dependent and highly variable. Gene-therapy trials carry binary risk, and 4D-150 must compete against established anti-VEGF therapies and other emerging approaches. Financing and dilution remain live concerns, while short interest of roughly 21% of shares outstanding and roughly $1.66 million in recent insider selling add to the overhang. A disappointing data readout could sharply re-rate the shares, making the target much harder to justify.
Technical Levels and Market Structure
The stock trades between its 200-day moving average near $11 and its 50-day average near $13.35, suggesting a broad consolidation after a volatile 12 months. Key support sits around the $11.00–$10.80 zone, while resistance is layered near $13.50 and again at the 52-week high of $16.93. A decisive break above that high would be required before the $31 target even becomes a realistic technical consideration. From what I see, the technical picture remains range-bound for now.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the 4D-150 data catalysts stretch into 2027, so individual assumptions differ materially. Investors should watch the upcoming quarterly report, enrollment and data timelines for the 4FRONT program, any financing or partnership announcements, changes in analyst targets and ratings, and shifts in short interest. Biotech-sector risk appetite and interest-rate dynamics also matter for this high-beta name. I’m watching this closely as the next catalysts approach.
AI Daily Buy/Sell Signals
In my research process, Tickeron’s AI Daily Buy/Sell Signals provide a useful way to monitor shifting conditions on names like this one.
Final Assessment
Can FDMT reach $31? The target, an average of seven current analyst price targets, sits about 148% above the latest price — a very large move that hinges almost entirely on the clinical and commercial success of 4D-150. Strong cash reserves, early Phase 3 enrollment, and a bullish analyst tilt support the ambition, but persistent losses, binary data risk, high short interest, and a wide $20-to-$37 target range underscore the uncertainty. The next data readouts and financing decisions, not near-term earnings, are likely to determine whether the gap toward $31 can narrow.
Exploring AI Tools for Biotech Analysis
In my own workflow, I often rely on Tickeron’s AI Daily Buy/Sell Signals to scan for signals across volatile names. The platform uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For event-driven names like FDMT, this kind of automated review helps surface opportunities and track trends more efficiently alongside traditional analysis. It has become a regular part of how I cross-check ideas before focusing on the fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FDMT in downward trend: 10-day moving average broke below 50-day moving average on October 08, 2026
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
FDMT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FDMT's RSI Indicator exited the oversold zone, 24 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 57 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 76 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement